31 results on '"Dudnik E"'
Search Results
2. EP08.02-047 The Impact of CGP on the Decision-making Process in ALK+ aNSCLC After Failure of 2nd/3rd-Generation ALK TKIs
3. P2.16-05 Durvalumab+EP in Advanced Large-Cell Neuroendocrine Carcinoma of Lung (aLCNEC): a Pilot Phase II study
4. P1.21-14 LIPI-based Score Predicting OS Benefit for the Addition of Chemotherapy to Pembrolizumab in aNSCLC with PD-L1 TPS≥50%
5. 133TiP Neoadjuvant osimertinib followed by sequential definitive radiotherapy and/or surgery in stage III EGFR-mutant NSCLC: An open-label, single-arm, phase II study
6. EP08.02-122 Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP)
7. P47.10 Neoadjuvant Osimertinib in EGFR-Mutant Stage IIIA/B NSCLC - A Phase 2 Open-Label Pilot Study
8. FP12.02 Pembrolizumab as a Monotherapy or in Combination With Platinum-Based Chemotherapy in NSCLC: Correlation With Blood Biomarkers
9. P84.10 The Impact of 3rd-Line ALK Inhibitors in ALK Positive NSCLC in Real-World Data
10. P84.03 GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients
11. P50.04 Real-World Survival Outcomes with Immune Checkpoint Inhibitors in Large Cell Neuroendocrine Tumors of Lung
12. P21.11 Durvalumab after Concurrent cChemotherapy and High-Dose Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer
13. P09.21 Blood Pressure Variability in Lung Cancer Patients Receiving Chemotherapy
14. P2.06-14 BAP1 Mutant Malignant Pleural Mesothelioma (MPM): Outcomes with Chemotherapy, ICPi and PARPi
15. OA11.06 Alternative Nivolumab (N) Duration and Scheduling in Advanced Non-Small Cell Lung Cancer (aNSCLC): Real-Life Data
16. P3.04-28 Can Ipilimumab Restore Immune Response in Advanced NSCLC After Progression on Anti PD1/PDL1 Agents?
17. P3.01-28 The Clinical Impact of Comprehensive cfDNA Genomic Testing in Lung Cancer
18. P2.12-14 Stereotactic Radiosurgery for Brain Metastases in Small Cell Lung Cancer.
19. P2.01-02 Osimertinib for EGFR-Positive Advanced NSCLC with Brain Metastases: Preliminary Analysis of an Open-Label, Two-Arm, Phase 2 Study
20. P1.04-30 A Potential Effect of Diabetes Mellitus and Metformin Use on Efficacy of Immune Checkpoint Inhibitors (ICI)
21. P1.04-17 Tumour Burden as a Predictive Tool of Response to Immune Checkpoint Inhibitors (ICI) in Patients with Metastatic Non-Small-Cell Lung Cancer
22. 146P The clinical impact of comprehensive cfDNA genomic testing in lung cancer
23. 145P Impact of next-generation sequencing on survival in lung cancer
24. P3.13-030 Metabolic Parameters of FDG PET at Early Evaluation of NSCLC Differ with Histological Subtypes
25. P3.01-060 The Clinical Utility of ctDNA Gene Analysis in Lung Cancer
26. P3.01-056 Intracranial Activity of Osimertinib in Naïve EGFRm T790M(-)And Treated EGFRm T790M(+) NSCLC Patients with Asymptomatic Brain Metastases
27. P1.01-039 Survival Impact of Next-Generation Sequencing in Lung Cancer
28. MA 02.06 BRAF Mutant NSCLC: Correlation with PD-L1 Expression,TMB, MSI and Response to ICPi and Anti-BRAF Therapy
29. 181P Anti-PD-1 antibodies in non-small cell lung cancer (NSCLC): The real-life setting experience
30. 182P Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases
31. 152P The clinical utility of next-generation sequencing in lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.